6533b85cfe1ef96bd12bc949
RESEARCH PRODUCT
Treatment of Severe Reactive Hypoglycemia With a Somatostatin Analogue (SMS 201-995)
J. BeyerU. KrauseJuergen SchrezenmeirPeter WeberHendrik Lehnertsubject
Blood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousHypoglycemiaOctreotideRefractoryInternal medicineInternal MedicinemedicineHumansInsulinOral glucose toleranceSevere disorderGlucose tolerance testReactive hypoglycemiaC-Peptidemedicine.diagnostic_testbusiness.industryGlucose Tolerance TestMiddle Agedmedicine.diseaseHypoglycemiaSomatostatin AnaloguePostprandialEndocrinologyFoodbusinessdescription
• Reactive (or postprandial) hypoglycemia can sometimes represent a severe disorder refractory to conventional therapeutic measures. We present in this first individual trial, to our knowledge, that the administration of a somatostatin analogue (SMS 201 -995) may alleviate the severity of complaints and does not appear to be diabetogenic. The effects of the somatostatin analogue were documented in a 5-hour oral glucose tolerance test, where not only the glucose-induced and C-peptide rise was clearly attenuated, but also the blood glucose concentration did not fall low enough to induce hypoglycemic symptoms. ( Arch Intern Med. 1990;150:2401-2402)
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1990-11-01 | Archives of Internal Medicine |